Mayo Clinic Proceedings Home

Safety and Efficacy of Extracorporeal Shock Wave Myocardial Revascularization Therapy for Refractory Angina Pectoris



      To assess the safety and efficacy of extracorporeal shockwave myocardial revascularization (ESMR) therapy in treating patients with refractory angina pectoris.

      Patients and Methods

      A single-arm multicenter prospective trial to assess safety and efficacy of the ESMR therapy in patients with refractory angina (class III/IV angina) was performed. Screening exercise treadmill tests and pharmacological single-photon emission computed tomography (SPECT) were performed for all patients to assess exercise capacity and ischemic burden. Patients were treated with 9 sessions of ESMR to ischemic areas over 9 weeks. Efficacy end points were exercise capacity by using treadmill test as well as ischemic burden on pharmacological SPECT at 4 months after the last ESMR treatment. Safety measures included electrocardiography, echocardiography, troponin, creatine kinase, and brain natriuretic peptide testing, and pain questionnaires.


      Fifteen patients with medically refractory angina and no revascularization options were enrolled. There was a statistically significant mean increase of 122.3±156.9 seconds (38% increase compared with baseline; P=.01) in exercise treadmill time from baseline (319.8±157.2 seconds) to last follow-up after the ESMR treatment (422.1±183.3 seconds). There was no improvement in the summed stress perfusion scores after pharmacologically induced stress SPECT at 4 months after the last ESMR treatment in comparison to that at screening; however, SPECT summed stress score revealed that untreated areas had greater progression in ischemic burden vs treated areas (3.69±6.2 vs 0.31±4.5; P=.03). There was no significant change in the mean summed echo score from baseline to posttreatment (0.4±5.1; P=.70). The ESMR therapy was performed safely without any adverse events in electrocardiography, echocardiography, troponins, creatine kinase, or brain natriuretic peptide. Pain during the ESMR treatment was minimal (a score of 0.5±1.2 to 1.1±1.2 out of 10).


      In this multicenter feasibility study, ESMR seems to be a safe and efficacious treatment for patients with refractory angina pectoris. However, larger sham-controlled trials will be required to confirm these findings.

      Abbreviations and Acronyms:

      BNP (brain natriuretic peptide), CAD (coronary artery disease), CK (creatine kinase), ECG (electrocardiogram/electrocardiographic), ESMR (extracorporeal shockwave myocardial revascularization), ETT (exercise treadmill test), SDS (summed difference score), SPECT (single-photon emission computed tomography), SRS (summed rest score), SSS (summed stress score), SWA (shock wave applicator)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Roger V.L.
        • Go A.S.
        • Lloyd-Jones D.M.
        • et al.
        Heart disease and stroke statistics—2012 update: a report from the American Heart Association [published correction appears in Circulation. 2012;125(22):e1002].
        Circulation. 2012; 125: e2-e220
        • Williams B.
        • Menon M.
        • Satran D.
        • et al.
        Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality.
        Catheter Cardiovasc Interv. 2010; 75: 886-891
        • Kiernan T.J.
        • Boilson B.A.
        • Sandhu G.S.
        • et al.
        Nonrevascularizable coronary artery disease following coronary artery bypass graft surgery: a population-based study in Olmsted County, Minnesota.
        Coron Artery Dis. 2009; 20: 106-111
        • McGillion M.
        • L'Allier P.L.
        • Arthur H.
        • et al.
        Recommendations for advancing the care of Canadians living with refractory angina pectoris: a Canadian Cardiovascular Society position statement.
        Can J Cardiol. 2009; 25: 399-401
        • Wilson S.R.
        • Scirica B.M.
        • Braunwald E.
        • et al.
        Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
        J Am Coll Cardiol. 2009; 53: 1510-1516
        • Tardif J.C.
        • Ponikowski P.
        • Kahan T.
        • ASSOCIATE Study Investigators
        Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial.
        Eur Heart J. 2009; 30: 540-548
        • Barsness G.
        • Feldman A.M.
        • Holmes Jr., D.R.
        • Holubkov R.
        • Kelsey S.F.
        • Kennard E.D.
        The International EECP Patient Registry (IEPR): design, methods, baseline characteristics, and acute results.
        Clin Cardiol. 2001; 24: 435-442
        • Hautvast R.W.
        • DeJongste M.J.
        • Staal M.J.
        • van Gilst W.H.
        • Lie K.I.
        Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study.
        Am Heart J. 1998; 136: 1114-1120
        • Saririan M.
        • Eisenberg M.J.
        Myocardial laser revascularization for the treatment of end-stage coronary artery disease.
        J Am Coll Cardiol. 2003; 41: 173-183
        • van Ramshorst J.
        • Bax J.J.
        • Beeres S.L.
        • et al.
        Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial.
        JAMA. 2009; 301: 1997-2004
        • Losordo D.W.
        • Henry T.D.
        • Davidson C.
        • et al.
        Intramyocardial, autologous CD34+ cell therapy for refractory angina.
        Circ Res. 2011; 109: 428-436
        • Friis T.
        • Haack-Sørensen M.
        • Mathiasen A.B.
        • et al.
        Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina.
        Scand Cardiovasc J. 2011; 45: 161-168
        • Kastrup J.
        • Jørgensen E.
        • Rück A.
        • et al.
        Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject One trial.
        J Am Coll Cardiol. 2005; 45: 982-988
        • Henry T.D.
        • Annex B.H.
        • McKendall G.R.
        • et al.
        The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.
        Circulation. 2003; 107: 1359-1365
        • Nishida T.
        • Shimokawa H.
        • Oi K.
        • et al.
        Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo.
        Circulation. 2004; 110: 3055-3061
        • Mariotto S.
        • de Prati A.C.
        • Cavalieri E.
        • Amelio E.
        • Marlinghaus E.
        • Suzuki H.
        Extracorporeal shock wave therapy in inflammatory diseases: molecular mechanism that triggers anti-inflammatory action.
        Curr Med Chem. 2009; 16: 2366-2372
        • Aicher A.
        • Heeschen C.
        • Sasaki K.
        • Urbich C.
        • Zeiher A.M.
        • Dimmeler S.
        Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia.
        Circulation. 2006; 114: 2823-2830
        • Uwatoku T.
        • Ito K.
        • Abe K.
        • et al.
        Extracorporeal cardiac shock wave therapy improves left ventricular remodeling after acute myocardial infarction in pigs.
        Coron Artery Dis. 2007; 18: 397-404
        • Zuoziene G.
        • Laucevičius A.
        • Leibowitz D.
        Extracorporeal shockwave myocardial revascularization improves clinical symptoms and left ventricular function in patients with refractory angina.
        Coron Artery Dis. 2012; 23: 62-67
        • Bruce R.A.
        Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation.
        Ann Clin Res. 1971; 3: 323-332
        • Gibbons R.J.
        • Balady G.J.
        • Bricker J.T.
        • et al.
        • American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Committee to Update the 1997 Exercise Testing Guidelines
        ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) [published correction appears in J Am Coll Cardiol. 2006;48(8):1731].
        J Am Coll Cardiol. 2002; 40: 1531-1540
        • Henzlova M.J.
        • Cerqueira M.D.
        • Mahmarian J.J.
        • Yao S.S.
        • Quality Assurance Committee of the American Society of Nuclear Cardiology
        Stress protocols and tracers.
        J Nucl Cardiol. 2006; 13: e80-e90
        • Cerqueira M.D.
        • Weissman N.J.
        • Dilsizian V.
        • et al.
        • American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging
        Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.
        Circulation. 2002; 105: 539-542
        • Chaussy C.
        • Brendel W.
        • Schmiedt E.
        Extracorporeally induced destruction of kidney stones by shock-waves.
        Lancet. 1980; 2: 1265-1268
        • Preminger G.M.
        • Tiselius H.G.
        • Assimos D.G.
        • et al.
        • EAU/AUA Nephrolithiasis Guideline Panel
        2007 guideline for the management of Ureteral calculi.
        J Urol. 2007; 178: 2418-2434
        • Fisher A.B.
        • Chien S.
        • Barakat A.I.
        • Nerem R.M.
        Endothelial cellular response to altered shear stress.
        Am J Physiol Lung Cell Mol Physiol. 2001; 281: L529-L533
        • Wang F.S.
        • Wang C.J.
        • Huang H.J.
        • Chung H.
        • Chen R.F.
        • Yang K.D.
        Physical shock wave mediates membrane hyperpolarization and Ras activation for osteogenesis in human bone marrow stromal cells.
        Biochem Biophys Res Commun. 2001; 287: 648-655
        • Yoshida J.
        • Ohmori K.
        • Takeuchi H.
        • et al.
        Treatment of ischemic limbs based on local recruitment of vascular endothelial growth factor-producing inflammatory cells with ultrasonic microbubble destruction.
        J Am Coll Cardiol. 2005; 46: 899-905
        • Yan X.
        • Zeng B.
        • Chai Y.
        • Luo C.
        • Li X.
        Improvement of blood flow, expression of nitric oxide, and vascular endothelial growth factor by low-energy shockwave therapy in random-pattern skin flap model.
        Ann Plast Surg. 2008; 61: 646-653
        • Wang C.J.
        • Huang H.Y.
        • Pai C.H.
        Shock wave-enhanced neovascularization at the tendon-bone junction: an experiment in dogs.
        J Foot Ankle Surg. 2002; 41: 16-22
        • Young S.R.
        • Dyson M.
        The effect of therapeutic ultrasound on angiogenesis.
        Ultrasound Med Biol. 1990; 16: 261-269
        • Stephenson T.J.
        • Johnson A.G.
        • Ross B.
        Short-term effects of extracorporeal shock wave lithotripsy on the human gallbladder.
        J Pathol. 1989; 158: 239-246
        • Grunewald M.
        • Avraham I.
        • Dor Y.
        • et al.
        VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells.
        Cell. 2006; 124: 175-189
        • Fukumoto Y.
        • Ito A.
        • Uwatoku T.
        • et al.
        Extracorporeal cardiac shock wave therapy ameliorates myocardial ischemia in patients with severe coronary artery disease.
        Coron Artery Dis. 2006; 17: 63-70
        • Khattab A.A.
        • Brodersen B.
        • Schuermann-Kuchenbrandt D.
        • et al.
        Extracorporeal cardiac shock wave therapy: first experience in the everyday practice for treatment of chronic refractory angina pectoris.
        Int J Cardiol. 2007; 121: 84-85
        • Kikuchi Y.
        • Ito K.
        • Ito Y.
        • et al.
        Double-blind and placebo-controlled study of the effectiveness and safety of extracorporeal cardiac shock wave therapy for severe angina pectoris.
        Circ J. 2010; 74: 589-591
        • Hasdai D.
        • Gibbons R.J.
        • Holmes Jr., D.R.
        • Higano S.T.
        • Lerman A.
        Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects.
        Circulation. 1997; 96: 3390-3395